a summary of the manufacturer or sponsor of the technology's (referred to as the company) submission, the ERG review and the resulting NICE guidance issued in March 2016. The main clinical effectiveness data were derived from two good-quality multicentre randomised controlled trials (RCTs): COM-FORT-II compared ruxolitinib with best available therapy (BAT) and COMFORT-I compared ruxolitinib with placebo. Both RCTs demonstrated a statistically significant reduction in splenomegaly and its associated symptoms in intermediate-2 and high-risk myelofibrosis patients. Overall survival was statistically significantly improved with ruxolitinib compared with BAT at 3.5 years of follow-up in the COMFORT-II trial (hazard ratio 0.58, 95 % CI 0.36-0.93). Grade 3-4 adverse events were more frequent in the ruxolitinib group than in the BAT group; 42 % compared with 25 %. Evidence relating to patients with lower-risk disease or low platelet counts (50-100 9 10 9 /L) was less robust. The company's economic model was well-presented and had an appropriate model structure. The base-case incremental cost-effectiveness ratio (ICER) was estimated to be around £45,000 per quality-adjusted life-year (QALY) gained (including the PAS discount). Extensive sensitivity and scenario analyses were presented, demonstrating that the estimated ICER was robust to a range of input values and assumptions made in the model. Alternative scenarios presented by the ERG showed only modest increases in the estimated ICER, primarily as a result of including an element of drug wastage within the model. Alternative scenarios resulted in estimated ICERs ranging from around £45,000 to £49,000 per QALY gained (including the PAS discount). At the first appraisal meeting, the NICE Appraisal Committee concluded that ruxolitinib was clinically effective and was a cost effective use of National Health Service (NHS) resources for patients with high-risk myelofibrosis who meet NICE's end-of-life criteria. Following the consultation, the company offered a revised PAS, resulting in a revised base-case ICER of £31,229 per QALY gained. The company also presented new evidence on the cost effectiveness of ruxolitinib in intermediate-2 and high-risk subgroups and a revised version of the model. The NICE Appraisal Committee considered the new evidence and recommended ruxolitinib for the treatment of patients with intermediate-2-risk disease as well as patients with high-risk disease, based on International Prognostic Scoring System (IPSS) prognostic factors.
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Introduction
The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance to the National Health Service (NHS) in England on the use of selected new health technologies. Single Technology Appraisals (STAs) evaluate a single product, device or other technology that has a single indication, for example a new pharmaceutical product or licensed indication [1] . The manufacturer or sponsor of the technology (hereafter referred to as the company) submits the principal evidence supporting the clinical and cost effectiveness of the product, and an external independent academic organisation (the Evidence Review Group [ERG] ) is commissioned to produce a review and critique of the evidence submitted [2] . Clinical specialists, NHS commissioning experts and patient experts also provide evidence for consideration by the NICE Appraisal Committee in formulating their guidance [1] . Once published, NICE technology guidance provides a legal obligation for NHS providers to reimburse technologies that have been recommended [1] .
Ruxolitinib has previously been assessed as part of the STA process and was not recommended for the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis in NICE guidance issued in June 2013 (TA289), although it was made available via the National Cancer Drugs Fund. However, longer-term survival data became available and a price discount patient access scheme (PAS) was introduced and, therefore, a review of TA289 was commissioned.
This article presents a summary of the ERG's independent critique of the company's submission to NICE and its role in the subsequent development of NICE guidance for the use of ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis (review of TA289). The key issues that arose during the review process and subsequent committee decision making are summarised. Full details of the appraisal and the relevant documents can be found on the NICE website [3] .
The Decision Problem
Myelofibrosis is a myeloproliferative neoplasm which can develop de novo as primary myelofibrosis (PMF) or secondary to polycythaemia vera or essential thrombocythaemia, known as post-polycythaemia vera myelofibrosis (PPV-MF) and post-essential thrombocythaemia myelofibrosis (PET-MF). PMF, PPV-MF and PET-MF patients share a common transformation in the early haematopoietic stem cell of the Janus-associated kinase (JAK) 2 gene. The JAK/STAT (signal transducer and activator of transcription) pathway is essential for normal haematopoiesis, inflammatory responses and immune function. However, in patients with myelofibrosis, there is over-activation of the JAK/STAT signalling pathway, resulting in over-proliferation of blood cell precursors. Bone marrow becomes replaced with scar tissue, resulting in bone marrow failure and extramedullary haematopoiesis (blood cell production outside the bone marrow, in the liver and spleen), which results in swelling of the liver and spleen.
Myelofibrosis is a rare and debilitating disease associated with substantial morbidity and early mortality. The clinical features of myelofibrosis include splenomegaly (enlarged spleen), fatigue, pain, early satiety, dyspnoea, weight loss, night sweats, pruritis (itching) and progressive anaemia. Late-stage myelofibrosis may transform to acute myeloid leukaemia. Survival varies considerably; median survival following diagnosis for patients with PMF is 4.0-5.7 years overall, while for patients with secondary myelofibrosis, median survival following diagnosis is 5.7-7.5 years [4] [5] . A later study by the IWG-MRT developed a second risk score: the Dynamic IPSS (DIPSS) [6] . Using the DIPSS, median survival was not reached in patients with low-risk disease; it was 14.2 years in intermediate-1-risk disease, 4 years in intermediate-2-risk disease and 1.5 years in high-risk disease [6] . The prevalence of myelofibrosis is estimated to be 2.2 per 100,000 population [4] .
The only curative treatment for myelofibrosis is haematopoietic stem cell transplantation; however, it is unsuitable for most patients and is associated with a high risk of complications and death. Therefore, clinical management focuses on symptom control. Treatments such as hydroxycarbamide, corticosteroids and thalidomide are commonly used in the UK and are recommended for use by the British Committee for Standards in Haematology (BCSH) guidelines [7] . The BCSH guideline for the diagnosis and management of myelofibrosis was revised in 2014 to include the recommendation of ruxolitinib as first-line therapy for symptomatic splenomegaly and/or myelofibrosis-related constitutional symptoms regardless of JAK2 V617F mutation status [8] .
Ruxolitinib is a JAK2 inhibitor licensed for the treatment of disease-related splenomegaly or symptoms in adult patients with PMF, PPV-MF or PET-MF. Ruxolitinib has previously been assessed as part of the STA process and was not recommended for the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis in NICE guidance issued in June 2013 (TA289) [9] , although it was made available via the National Cancer Drugs Fund. However, longer-term survival data became available and a price discount PAS was introduced and, therefore, a review of TA289 was commissioned. The NICE appraisal scope requested clinical and cost-effectiveness evidence for ruxolitinib with established clinical practice, compared with established clinical practice without ruxolitinib.
The Independent Evidence Review Group (ERG) Review
The company provided a submission to NICE on the use of ruxolitinib in the treatment of disease-related splenomegaly and symptoms in adults with myelofibrosis. The ERG critically reviewed the evidence presented in the company's submission by assessing (1) whether the submission conformed to NICE methodological guidelines; (2) whether the company's interpretation and analysis of the evidence were appropriate; and (3) the presence of other evidence or alternative interpretations of the evidence. In addition, the ERG identified areas requiring clarification, for which the company provided additional evidence [10] .
Clinical Evidence
The company's submission incorporated a systematic review of studies evaluating the efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
The main clinical effectiveness data were derived from two good-quality multicentre randomised controlled trials (RCTs): COMFORT (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment)-II compared ruxolitinib with best available therapy (BAT) [11] and COMFORT-I compared ruxolitinib with placebo [12] . Both RCTs included patients with intermediate-2 or high-risk myelofibrosis. The ERG did not identify any additional relevant RCTs. Both RCTs demonstrated a statistically significant reduction in splenomegaly and its associated symptoms in intermediate-2 and high-risk myelofibrosis patients. In COMFORT-II, 28 % of ruxolitinib patients achieved a 35 % or greater reduction in spleen volume at week 48 (the primary outcome) compared with 0 % of BAT patients (p \ 0.001), with a mean change in spleen volume of -30.1 versus ?7.3 % (p \ 0.001). The median time to initial response was 12.3 weeks in the ruxolitinib group, with 80 % of responders maintaining a response at a median follow-up of 12 months. The median duration of maintenance of spleen response was 2.76 years in the ruxolitinib group [11] . In COMFORT-I, 42 % of ruxolitinib patients achieved a 35 % or greater reduction in spleen volume at week 24 (the primary outcome) compared with 0.7 % of patients in the placebo group (p \ 0.001), with a mean change in spleen volume of -31.6 versus ?8.1 %. Most patients who achieved a 35 % or greater reduction in spleen volume had achieved this by week 12, with 67 % of responders maintaining a response at a median follow-up of 48 weeks [12] . In both COMFORT trials, improvements in splenomegaly were observed in the control group when patients crossed over to receive ruxolitinib [11, 12] .
Both COMFORT trials reported significant improvements in myelofibrosis-associated symptoms and healthrelated quality of life (HR-QOL) compared with patients treated with BAT or placebo, measured using the diseasespecific European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer TherapyLymphoma (FACT-Lym) scale and/or the modified Myelofibrosis Symptom Assessment Form (MFSAF) version 2 [11, 12] . In both COMFORT trials there were greater improvements in global health status/quality of life in the ruxolitinib group than the control group, statistically significantly so in the COMFORT-I trial [12] . In the COMFORT-I trial, significantly more ruxolitinib patients achieved a 50 % or greater reduction in total symptom score using the MFSAF at week 24 than patients in the placebo group (45.9 vs. 5.3 %). Ruxolitinib patients had a 46.1 % mean improvement in total symptom score at 24 weeks compared with a 41.8 % mean worsening in the total symptom score in the placebo group [12] .
When compared with BAT in the COMFORT-II trial, ruxolitinib improved OS, reaching borderline statistical significance at a median of 112 weeks' follow-up (hazard ratio [HR] 0.52, 95 % CI 0.27-1.00), and statistical significance at a median of 3 years (HR 0.48, 95 % CI 0.28-0.85) and 3.5 years of follow-up (HR 0.58, 95 % CI 0.36-0.93) [13, 14] . Compared with placebo, ruxolitinib statistically significantly improved OS at a median followup of 51 weeks (HR 0.50, 95 % CI 0.25-0.98) [12] and 102 weeks (HR 0.58, 95 % CI 0.36-0.95) in the COM-FORT-I trial [15] . However, the OS benefit did not reach statistical significance at 3 years (HR 0.69, 95 % CI 0.46-1.03) [16] . Neither trial was designed to be sufficiently powered to detect a statistically significant difference in OS. In addition, the majority of patients in the BAT and placebo groups crossed over to receive ruxolitinib during the course of the trial; therefore, the analyses are likely to underestimate the survival benefit of ruxolitinib. The company presented an OS analysis with adjustment for crossover, using a rank-preserving structural failure time model (RPSFTM). The RPSFTM analysis resulted in a larger reduction in the risk of death with ruxolitinib compared with BAT or placebo than that seen using an intention-to-treat (ITT) analysis; however, the results compared with placebo still did not reach statistical significance [4] .
Median OS was not reached in the ruxolitinib arm of either of the COMFORT trials; therefore, it was not possible to calculate the median (or mean) survival benefit associated with ruxolitinib compared with BAT or placebo. However, the company submission included a summary of an indirect comparison made between 100 PMF patients from the ruxolitinib arm of the COMFORT-II trial and 350 patients from the DIPSS cohort (a database of 519 PMF patients) [4] . The number of observed deaths in the two cohorts was 30 (30 %) on ruxolitinib and 256 (86 %) on conventional care, generating estimates of median survival of 5 years (95 % CI 2.9-7.8) on ruxolitinib compared with 3.5 years (95 % CI 3.0-3.9) for the DIPSS cohort [17] .
Grade 3-4 adverse events were more frequent in the ruxolitinib group than the BAT group: 42 % compared with 25 % [11] . The most frequently occurring grade 3-4 adverse events were anaemia and thrombocytopenia, which were generally managed by dose modifications and/or blood transfusions and rarely led to treatment discontinuation. Haemoglobin levels decrease rapidly following initiation of ruxolitinib treatment but then increase over time, almost returning to the baseline level. Platelet levels decrease rapidly following initiation of ruxolitinib treatment but then remain reasonably constant. Other adverse events affecting more than 20 % of ruxolitinib patients were diarrhoea, peripheral oedema and fatigue, although fatigue and peripheral oedema were also frequently reported in the placebo and BAT groups [11, 12] . In the COMFORT-II trial, 72 % of patients in the ruxolitinib group and 18 % of patients in the BAT group required dose reductions or interruptions due to adverse events; thrombocytopenia was the most common reason for dose modifications [11] .
In the COMFORT-II trial, 38 % ruxolitinib patients had discontinued treatment by 48 weeks [11] . By a median of 3.5 years of follow-up, 63 % ruxolitinib patients had discontinued treatment, primarily because of adverse events (20 %) and disease progression (18 %) [14] . Of those patients who had crossed over to ruxolitinib from the BAT arm, 60 % had discontinued treatment by 3.5 years of follow-up, primarily because of adverse events (18 %) [14] . In the COMFORT-I trial, 50 % of patients had discontinued treatment by 3 years of follow-up, primarily because of disease progression (23 %) [16] .
The company submission also described four non-RCT studies that included patients who were not eligible for the COMFORT trials: ROBUST, JUMP (JAK Inhibitor Ruxolitinib in Myelofibrosis Patients), Study 258 and EXPAND. The ROBUST study was a small phase II study of patients from the UK who had intermediate-1, intermediate-2 or high-risk disease [18] . The JUMP study was a large phase IIIb extended-access study in 25 countries for patients who had intermediate-1, intermediate-2 or highrisk disease [19] . Study 258 was a small phase II dosefinding study of patients with low platelet counts (50-100 9 10
The results of the non-RCT studies were generally consistent with the COMFORT trials, suggesting that ruxolitinib may also be effective at reducing spleen size and symptoms in patients with intermediate-1-risk myelofibrosis and patients with a low platelet count (50-99 9 10 9 /L), although adverse events were more frequently reported in patients with a low platelet count, particularly thrombocytopenia, as might be expected. Three of the non-RCT studies were very small and none had a non-ruxolitinib control group; therefore, evidence relating to patients with lower-risk disease or low platelet counts was less robust [18] [19] [20] [21] .
Critique of the Clinical Evidence
The company's systematic review did not appear to have missed any relevant RCTs. The two included RCTs were good quality and the results are likely to be reliable. However, both were conducted in patients with intermediate-2 or high-risk myelofibrosis and a platelet count of 100 9 10 9 /L or higher; therefore, the results are only generalizable to this subgroup of myelofibrosis patients, rather than the full licensed population [11, 12] . Four non-RCT studies that included patients with intermediate-1-risk disease and platelet counts between 50 and 100 9 10 9 /L were also described, although the results of these smaller studies without a non-ruxolitinib control group are less reliable [18] [19] [20] [21] .
Significantly more patients in the ruxolitinib group than in the control group in both COMFORT trials met the primary endpoint of achieving a 35 % or greater reduction in spleen volume [11, 12] . However, 63 % of patients had discontinued treatment at 3.5 years' follow-up in the COMFORT-II trial [11] and half of the patients in the COMFORT-I trial had discontinued treatment at 3 years' follow-up, primarily because of disease progression or adverse events [12] . Therefore, there is some uncertainty about the long-term effectiveness and tolerability of ruxolitinib.
The results relating to myelofibrosis-associated symptoms are likely to be reliable; ruxolitinib was associated with clinically meaningful improvements in myelofibrosisassociated symptoms. HR-QOL appeared to be improved with ruxolitinib, although data were missing for a large proportion of patients for some of the quality-of-life results; therefore, the reliability and generalisability of these results is unclear [11, 12] .
Despite the fact that the COMFORT-II trial was not designed to be sufficiently powered to detect a statistically significant difference between treatment groups, and the crossover nature of the trial, OS was statistically significantly improved with ruxolitinib compared with BAT at the later timepoints (3 and 3.5 years) using both ITT and RPSFTM analyses. The RPSFTM was used to estimate the true effect of ruxolitinib on OS, adjusting for crossover. The company also considered the two-stage approach and the iterative parameter estimation (IPE) and the inverse probability of censoring weights (IPCW) methods, presenting their reasoning for choosing the RPSFTM over other methods of adjusting for crossover. Whilst all methods of adjusting survival estimates in the presence of treatment switching have limitations, the ERG considered the RPSFTM (which relies critically on the 'common treatment effect' assumption) to be appropriate in the present context. The OS benefit in the COMFORT-I trial did not reach statistical significance at the later timepoints, even after adjustment for crossover. Median survival was not reached, so the data were not mature and the duration of any survival benefit due to ruxolitinib could not be calculated from the trial data.
Evidence relating to patients with lower-risk disease or low platelet counts was less robust and further data from randomised studies are required to confirm the efficacy and tolerability of ruxolitinib in these populations.
Cost Effectiveness Evidence
The company presented a systematic review of the costeffectiveness studies of ruxolitinib for the treatment of myelofibrosis. Two studies were identified: one compared ruxolitinib to BAT from a Canadian societal perspective [22] and the other was the model presented in the previous STA of ruxolitinib [2] . Neither study was considered relevant and therefore a de novo model was developed.
The model submitted was an individual patient discrete event simulation model (Fig. 1) . The company justified the use of this approach on the basis that this type of model allows for increased flexibility and allows the progressive nature of myelofibrosis to be modelled in a more transparent way than a Markov model, which would require the excessive use of short-term 'temporary' states. The model compared ruxolitinib with BAT, which was assumed to consist of the basket of therapies used in the comparator arm of the COMFORT-II trial. The population modelled was intermediate-2 and high-risk myelofibrosis patients, consistent with the COMFORT-II trial. The primary outputs of the model were quality-adjusted life-years (QALYs) and costs. The model time horizon was 35 years, which was designed to simulate a lifetime time horizon. Both costs and benefits were discounted at 3.5 %, in line with NICE recommendations. An NHS and Personal Social Services (PSS) perspective was taken. Costs were separated into drug acquisition costs, costs associated with the management of myelofibrosis, adverse event costs, costs associated with leukaemic transformation and end-of-life costs. The economic model tracks changes in HR-QOL according to the different phases of treatment with utility values based on a time-trade-off (TTO) analysis of a newly developed condition-specific preference-based measure for myelofibrosis [23] . The new myelofibrosis-specific measure was based on two existing measures, the MFSAF and the EORTC QLQ-C30, from which items were selected to capture the factors determining disease severity.
The model contained four mutually exclusive health states, with 'alive' states being defined by therapy phase: on ruxolitinib (patients have some moderate improvement in symptoms and splenomegaly and HR-QOL); on BAT (limited symptom control with minimal impact on HR-QOL); on supportive care (associated with progressive worsening of symptoms until death); and death. A 24-week stopping rule was applied, where ruxolitinib treatment is only continued if patients are considered to be responding to treatment. This stopping rule is based on definitions of response set out in the IWG-MRT/ELN (European LeukemiaNet) guidelines [24] and includes both symptom response and spleen size response. Time in each 'health state' is dependent on initial treatment decision and treatment response and was modelled based on data on OS and time on treatment observed in the COMFORT-I and COMFORT-II trials.
The company's submission presented both deterministic and probabilistic sensitivity analyses to demonstrate the robustness of the estimated incremental cost-effectiveness ratio (ICER) along with extensive scenario analysis examining the impact of a number of structural assumptions made in the base-case model. The base-case ICER presented in the company's submission, including a PAS discount, was estimated to be £44,905 per QALY gained in the deterministic analysis and £44,625 per QALY gained in the probabilistic sensitivity analysis. The probability of ruxolitinib being a cost-effective strategy at thresholds of £30,000, £40,000 and £50,000 per QALY gained was 0.33, 4.32 and 95.02 %, respectively. The sensitivity and scenario analyses presented by the company showed that the ICER rarely exceeded £50,000 per QALY gained. Exceptions to this included reducing the time horizon to 5 years, using an alternative parametric function to estimate OS in BAT patients, and using ITT (rather than crossover-adjusted) analysis to estimate OS on BAT. None of these scenarios was considered particularly plausible.
Critique of the Cost Effectiveness Evidence
The ERG agreed that neither of the studies identified in the systematic review of cost-effectiveness studies of ruxolitinib was relevant to the appraisal. The Canadian study was not relevant to the UK and the UK study was part of the previous NICE STA submission for ruxolitinib and therefore based on more limited data.
The use of an individual patient discrete event simulation model appeared justified. Given the progressive nature of myelofibrosis, additional flexibility was needed to allow a number of structural assumptions of the model to be evaluated, which would not have been possible if a Markov structure had been adopted. The model structure was considered representative of how ruxolitinib is likely to be used in the NHS and the disease progression of myelofibrosis patients. The discrete event simulation structure adopted was, however, a more complex model structure than a Markov structure, placing additional demands on the available data. This required the company to make a number of assumptions, which, while mostly plausible and justified by the available evidence, were subject to a degree of uncertainty. These assumptions included: Fig. 1 Simplified schematic of the model structure. BAT best available therapy
• Post-discontinuation survival for patients initiating on ruxolitinib being the same for both early discontinuers and responders to treatment.
• Spleen responders and symptom responders were assumed to have spent the same amount of time on ruxolitinib and BAT, and assumed to have the same survival time.
• Time to death for patients on BAT was assumed to follow the same survival curve as used for discontinuation for reasons other than death.
• A 24-week survival benefit for non-responders was assumed for patients initiating on ruxolitinib.
The company's submission presented empirical justification and/or extensive scenario analysis for all of these assumptions and there was generally limited impact on the ICER generated. The scenario analysis, however, did not address the joint uncertainty of these assumptions and as such a degree of uncertainty over the overall impact of these structural assumptions remains unexplored.
Further to this, the ERG also identified the following issues with the model:
• For patients who were considered non-responders to ruxolitinib after an initial 24-week treatment period it is assumed that OS would be increased by 24 weeks over patients initiating on BAT. No clinical evidence was provided to support this assumption, and while the ERG accepts that some OS benefit may be experienced by these patients, the evidence does not support the OS benefit assumed in the model. • The comparator used in the model was BAT, which comprised a basket of treatments used in the COM-FORT-II trial. There were concerns regarding the composition of this basket of therapies and how well it represented UK practice. In particular, the inclusion of lenalidomide was considered inappropriate as this drug is rarely used in the UK. Furthermore, it was felt that this basket of therapies should have included allogeneic haematopoietic stem cell transplantation as, while not suitable for all myelofibrosis patients, it is the only curative therapy available for myelofibrosis and has been observed to result in significant survival benefit over other myelofibrosis treatments excluding ruxolitinib.
• The model presented in the company submission did not allow for any drug wastage. This was considered inappropriate due to the fact that adverse events are often managed with either dose reductions or interruptions.
• In the base-case model, the mortality rate for ruxolitinib responders while on treatment was based on mortality data from the COMFORT-II trial. The ERG considered this to be an inappropriate source given the limited sample size and infrequency of deaths in this population. The ERG therefore conducted an alternative analysis using an alternative mortality rate of 7.06 %, which was estimated using data on the mean time responders spent on ruxolitinib and mortality rates from UK life tables.
The ERG conducted a number of additional analyses considering a number of alternative assumptions and exploring their impact on the estimated ICER. Adjusting the survival rate for responders, removing lenalidomide from the BAT basket of therapies and assuming a 5 % rate of drug wastage individually had only a modest impact on the estimated ICER, which remained at less than £50,000 per QALY gained (including the PAS discount) in all scenarios.
An alternative base-case was presented by the ERG, based on a combination of a number of scenario analyses presented by the company and assuming a 5 % rate of drug wastage, excluding lenalidomide from the BAT basket of therapies, assuming that for non-responders time on BAT is adjusted for time spent on ruxolitinib and assuming that the BAT discontinuation rate is underestimated by 20 %. This alternative base case was presented assuming both a 0 % mortality rate for ruxolitinib responders and an alternative rate of 7.06 %, based on a crude estimate of expected mortality made by the ERG. Again, this had only a modest impact on the estimated ICER, which remained at less than £50,000 per QALY gained (including the PAS discount).
Conclusions of the ERG Review
Evidence from two good-quality RCTs demonstrated that ruxolitinib is effective at reducing splenomegaly and its associated symptoms and can increase OS in intermediate-2 and high-risk myelofibrosis patients who can tolerate ruxolitinib and remain on therapy. However, withdrawal rates were high, with more than half of patients having discontinued therapy after 3 years. Evidence relating to patients with lower-risk disease or low platelet counts (50-100 9 10 9 /L) was less robust. The de novo model was well-presented and had an appropriate model structure, which showed good validation with the trial data from the COMFORT-II study. The extensive sensitivity and scenario analyses presented showed the estimated ICER to be largely robust to a range of input values and assumptions made in the model. The alternative scenarios presented by the ERG showed only a modest increase in the estimated ICER, which remained at less than £50,000 per QALY gained (including the PAS discount).
National Institute for Health and Care
Excellence (NICE) Guidance
Preliminary Guidance
The NICE Appraisal Committee considered the evidence available on the clinical and cost effectiveness of ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis, alongside expert testimony from clinical specialists and patient representatives. It also took into account the effective use of NHS resources. The Committee deliberated over whether ruxolitinib for the treatment of myelofibrosis meets NICE's end-of-life criteria. The preliminary NICE recommendation, recorded in the appraisal consultation document (ACD), was that ruxolitinib was recommended for the treatment of disease-related splenomegaly or symptoms in adults with high-risk myelofibrosis that does meet the endof-life criteria and who have a life expectancy of less than 24 months. The Committee recognised that ruxolitinib was clinically effective and was a cost-effective use of NHS resources in this subgroup of patients, with an ICER likely to fall between £45,000 and £49,000 per QALY gained (including the PAS discount). However, ruxolitinib was not a cost-effective use of NHS resources and was not recommended for the treatment of disease-related splenomegaly or symptoms in adults with intermediate-risk myelofibrosis that does not meet the end-of-life criteria.
Company's Response to the Preliminary Guidance
In response to the ACD, the company provided a base case that was revised to account for (a) errors identified by the ERG on the inclusion of leukaemic transformation in the economic model; (b) adjusting the baseline utility by a factor of 10 %; (c) change to the treatment pathway for responders to ruxolitinib assuming responders spend time on BAT after ruxolitinib discontinuation (Fig. 2) ; and (d) the exclusion of lenalidomide. A revised PAS was also offered by the company. These changes resulted in a revised base-case ICER for ruxolitinib of £31,229 per QALY gained (including the revised PAS).
An exploratory analysis was conducted to illustrate the impact of myelofibrosis on caregivers' quality of life. The company justified this analysis on the basis that the NICE methods guide states that ''For the reference case, the perspective on outcomes should be all direct health effects, whether for patients or other people''. On this basis, the company explained that the debilitating impact of myelofibrosis on patients means that many will require care from family and friends and that this burden should potentially be considered when evaluating the impact of ruxolitinib therapy. However, there was a lack of evidence regarding the extent to which myelofibrosis affects the quality of life of caregivers. Therefore, a series of assumptions was made to estimate the impact of myelofibrosis on caregiver quality of life in the analysis which was not observed in the COMFORT trials. The assumptions related to caregiver quality of life were that 57.48 % of myelofibrosis patients required some help, the quality of life of 1.76 caregivers was affected for each of the myelofibrosis patients that needed care, caregivers of myelofibrosis patients on BAT experienced a 0.1 decrement to their utility, and caregivers' quality of life returned to that of the general population whilst on ruxolitinib. However, costs associated with caregivers were not included in the analysis. The exploratory analysis reduced the revised base-case ICER (including revised PAS) to £28,111 per QALY gained.
ERG Critique of the Response Submitted by the Company
The ERG reviewed the revised model. Two key drivers of the revised economic analysis were the inflation of the baseline utility by 10 %, and responders on ruxolitinib spending 30 % of their time alive on BAT, instead of 45 % after discontinuation of ruxolitinib. The adjustment of the baseline utility was supported by clinical opinion instead of any empirical data. The ERG recognised that some inflation may be appropriate as this could suitably represent the baseline utility of patients enrolled in COMFORT-II, although there was limited evidence to suggest an appropriate inflation factor. Therefore, the ERG was uncertain about the plausibility of the magnitude of the presented inflation factor, which was not considered a plausible scenario in the original analyses. The adjustment of the baseline utility had a large impact on the ICER.
The ERG noted that the original assumption that patients discontinuing ruxolitinib therapy moved directly to supportive care was potentially a conservative assumption. However, the ERG was concerned regarding the changes to this assumption implemented in the company's revised model. Specifically, the ERG noted that the revised 30 % rate was almost entirely arbitrary and based on minimal data. Furthermore, it is far from certain that all patients discontinuing ruxolitinib will transit to BAT and it is far more likely that only a proportion will. This was not reflected in the new assumption. This change to the model also made the optimistic assumption that patients on BAT following ruxolitinib therapy would have the same quality of life as those initiating on BAT. The assumption seems far from obvious as there is clear potential for patients on BAT following ruxolitinib therapy to have lower quality of life than those who initiate on BAT. There was therefore significant potential that this new assumption was overly optimistic and underestimated the ICER.
Therefore, the ERG carried out two scenario analyses. The first assumed no inflation to baseline utility and that patients moved directly to supportive care after discontinuation of ruxolitinib. The second assumed a 10 % inflation in baseline utility and that 30 % of patients' time after discontinuing ruxolitinib was spent on BAT. The ICERs for the analyses were £35,632 and £31,676, respectively, per QALY gained (with the revised PAS). The ERG considered the ICERs from these two scenarios to be at least as plausible as the ICER presented in the company's resubmission of £31,229 (with the revised PAS).
The exploratory analysis incorporating caregivers' quality of life within the economic analysis had a large impact on the ICER. However, the ERG was uncertain about the quality of the evidence used to justify this analysis, particularly due to the fact that the quality-of-life losses were observed in a different disease area. The ERG therefore considered this analysis to be subject to significant uncertainty.
Final NICE Guidance
Following the consultation on the preliminary guidance, the NICE Appraisal Committee released the following final guidance to the NHS (review of TA289) [25] .
Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with PMF (also known as chronic idiopathic myelofibrosis), post PPV-MF or PET-MF only:
• in people with intermediate-2 or high-risk disease; and • if the company provides ruxolitinib with the discount agreed in the PAS.
People whose treatment with ruxolitinib is not recommended in this NICE guidance, but whose treatment was started within the NHS before this guidance was published, should be able to continue treatment until they and their clinician consider it appropriate to stop.
ERG Conclusion
This was a typical example of the NICE STA process. This case study, however, highlights that even where the company submission is relatively strong, the ERG still has a role in interpreting the clinical and cost-effectiveness evidence submitted by companies.
The principal issues raised in this STA relate to the model approach taken by the company. The use of an individual patient discrete event simulation model can be considered relatively novel and it has a number of advantages over a Markov structure, allowing the progressive nature of myelofibrosis to be modelled in a more transparent way than would have been possible using a Markov model. It was, however, also clear that the use of a discrete event simulation model placed additional demands on the Fig. 2 Updated simplified schematic of the model structure. BAT best available therapy available data and the structure of the model did not always fit well with the data available in the COMFORT trials that were used to populate the model. As a consequence, the issues raised by the ERG focused largely on exploring the uncertainty around a number of inputs for which evidence from the COMFORT-I and COMFORT-II trials was least robust, and on how these data were incorporated into the economic model. Sensitivity and scenario analyses presented by both the company and the ERG, however, demonstrated that the results of the cost-effectiveness analysis were robust to a variety of input values and, as such, the estimated ICER did not exceed the cost-effectiveness threshold in any plausible scenarios.
